[Clinicopathological and prognostic characteristics of clear cell papillary renal cell carcinoma]. 2021

Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
Department of Urology, Peking University First Hospital, the Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China.

Objective: To analyze the epidemiological, clinicopathological and prognostic characteristics of clear cell papillary renal cell carcinoma (CCPRCC) based on Chinese patient population. Method: Patients with renal cell carcinoma diagnosed at Peking University First Hospital from June 2016 to June 2020 were included in this study based on the inclusion and exclusion criteria. All cases were grouped according to CCPRCC, clear cell renal cell carcinoma (ccRCC), and papillary renal cell carcinoma (pRCC), and the general clinical, postoperative pathological and follow-up data of the patients were retrospectively analyzed. Result: A total of 18 CCPRCC patients were enrolled in this study, accounting for 0.44% (18/4 110) of the postoperative pathologically confirmed renal cell carcinoma cases in our hospital during this time period. The age range of the included patients was 28-86 years old, with a median age of 49.5 years old. There were 11/18 males and 7/18 females. All CCPRCC patients had no family history of renal malignant tumors. Among them, only one patient with CCPRCC had related clinical symptoms, that was intermittent waist and abdomen pain, while the other 17 cases were found by physical examination without any related symptoms. Compared with ccRCC and pRCC, there was no significant difference in their end stage renal disease history(χ2ccRCC=0.291, χ2pRCC=1.161,all P>0.05). The maximum diameter of CCPRCC tumor was smaller than pRCC (χ2=-2.280,P =0.027) but not significantly different from ccRCC (χ2=-0.579,P =0.565). The majority of patients with CCPRCC were in pT1, their pathological stage was earlier than the other two types, and their overall survival was better than ccRCC and pRCC (P<0.05). Conclusion: CCPRCC is a type of renal cell carcinoma with unique epidemiology, clinicopathology and prognostic characteristics. Patients with this subtype have an earlier clinical stage and a better prognosis than ccRCC and pRCC.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
January 2022, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
December 2021, International journal of molecular sciences,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
January 2021, International journal of general medicine,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
August 2022, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
June 2008, Clinical and experimental nephrology,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
May 2017, Urology,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
January 2010, Cancer biomarkers : section A of Disease markers,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
January 2020, International braz j urol : official journal of the Brazilian Society of Urology,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
September 2019, Archives of pathology & laboratory medicine,
Y W Xu, and J C Zhou, and H B Xie, and W P Yang, and L Li, and K N Zhang, and K F Ma, and Y Q Gong, and Z Zhang, and L Cai, and K Gong
February 2014, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Copied contents to your clipboard!